Previous 10 | Next 10 |
There’s Blood In The Streets But Not For These Penny Stocks Today Are you looking for penny stocks to buy now? If so, you’re not alone but a big question being asked right now is “When will stocks go back up?” The last two days of market turmoil have sparked a m...
Marinus Pharmaceuticals (NASDAQ: MRNS ) : Q2 GAAP EPS of -$0.16 beats by $0.03 . More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Clinical trials remain on track, with Refractory Status Epilepticus (SE) trial expected to begin enrollment shortly CDKL5 deficiency disorder (CDD) pivotal topline results on track for Q3; Conference call to be scheduled to discuss CDD data release and business update Organiz...
The FDA has granted Rare Pediatric Disease Designation to Marinus Pharmaceuticals' ( MRNS +3.1% ) for its product candidate ganaxolone, an allosteric modulator of GABA A receptors, for CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. More n...
Penny Stock News Has Catapulted Shares Of These Companies This Week When it comes to penny stocks and news, more times than not, it acts as a catalyst. Before you leave this article and start looking for any stocks with news, you should understand something. When I say, catalyst, I’m ...
FSD Pharma (NASDAQ: HUGE ) +130% . on decision to surrender health Canada licenses for subsidiary FV Pharma. More news on: FSD Pharma Inc., Kandi Technologies Group, Inc., Edesa Biotech, Inc., Stocks on the move, , Read more ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the compa...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Charles (“Chuck”) Austin to its Board of Directors. “Chuck is a recogni...
Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020 CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020 First patient enrolled in Phase 2 Tuberous Sclerosis Complex trial Enrollment in PCDH19 proof-of-concept trial increases to 25-30 patients Pipeli...
RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and comme...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...